Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles Expressing Plasmodium falciparum Circumsporozoite Epitopes

We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of the Plasmodium falciparum circumsporozoite (CS) protein. When expressed in Escher...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Nardin, Elizabeth H., Oliveira, Giane A., Calvo-Calle, J. Mauricio, Wetzel, Kristiane, Maier, Carolin, Birkett, Ashley J., Sarpotdar, Pramod, Corado, Michael L., Thornton, George B., Schmidt, Annette
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Microbiology 2004
Предметы:
Microbial Immunity and Vaccines
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC523031/
https://ncbi.nlm.nih.gov/pubmed/15501783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/IAI.72.11.6519-6527.2004
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы